Drug Profile

Research programme: epigenetic cancer therapeutics - Beactica/Dong-A ST

Alternative Names: LSD1 programme; Lysine specific demethylase 1 programme

Latest Information Update: 28 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beactica; Dong-A ST
Developer Beactica
Class Antineoplastics; Small molecules
Mechanism of Action Histone demethylase inhibitors; Lysine specific demethylase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in Sweden
07 Sep 2022 Beactica Therapeutics terminates licensing agreement with Dong-A ST
31 Jan 2019 Research programme: epigenetic cancer therapeutics is available for licensing as of 31 Jan 2019. http://www.beactica.com/pipeline

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com